In the randomized phase II CITYSCAPE trial (NCT03563716), the combination of tiragolumab (anti-TIGIT) and atezolizumab was investigated as a first-line therapy for advanced NSCLC patients with PD-L1 expression (PD-L1 ≥ 1%). The gene discussed is CD274; the disease is non-small cell lung carcinoma.